Wild Type Transthyretin Amyloid Cardiomyopathy Hidden Under Ablation‐Refractory Atrial Arrhythmias and the Potential Contribution of Tafamidis in Rhythm Control

Ítems similars

• Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy
  per: Naoto Kuyama, et al.
  Publicat: (2024-05-01)
• Real-World Utilization Patterns, Safety, and Efficacy of Tafamidis in Patients With Hereditary Transthyretin Amyloidosis in Japan
  per: Hiroaki Konishi, PharmD, et al.
  Publicat: (2025-01-01)
• Wild Type Transthyretin Amyloid Cardiomyopathy Hidden Under Ablation‐Refractory Atrial Arrhythmias and the Potential Contribution of Tafamidis in Rhythm Control
  per: Tomoki Horie, et al.
  Publicat: (2026-02-01)
• A simple staging system using biomarkers for wild‐type transthyretin amyloid cardiomyopathy in Japan
  per: Naoya Nakashima, et al.
  Publicat: (2022-06-01)
• Concurrent Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patient Treated With Daratumumab and Tafamidis: A Case Report
  per: Taiki Nishihara, et al.
  Publicat: (2025-08-01)